Cargando…

Real-life comparison of efficacy and safety profiles of two prolonged-release tacrolimus formulations in de novo kidney transplant recipients: 24 months of follow-up

INTRODUCTION: Calcineurin inhibitors constitute a cornerstone of immunosuppressive therapy in kidney transplant recipients. There are two main formulations of tacrolimus (Tac) which exhibit a prolonged-release mode of action: Advagraf(®) (MR-4) and Envarsus(®) (LCPT). However, they are not bioequiva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czarnecka, Paulina, Czarnecka, Kinga, Baczkowska, Teresa, Lagiewska, Beata, Durlik, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858018/ https://www.ncbi.nlm.nih.gov/pubmed/36662740 http://dx.doi.org/10.1371/journal.pone.0278894

Ejemplares similares

Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation
por: Czarnecka, Kinga, et al.
Publicado: (2021)

Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
por: Czarnecka, Paulina, et al.
Publicado: (2022)

Are We on the Right Track for HCV Micro-Elimination? HCV Management Practices in Dialysis Centers in Poland—A National Cross-Sectional Survey
por: Czarnecka, Paulina, et al.
Publicado: (2023)

Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study
por: Czarnecka, Paulina, et al.
Publicado: (2023)

Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience
por: Czarnecka, Kinga, et al.
Publicado: (2022)

Kidney and Liver Tissue Tacrolimus Concentrations in Adult Transplant Recipients—The Influence of the Whole Blood and Tissue Concentrations on Efficiency of Treatment during Immunosuppressive Therapy
por: Bodnar-Broniarczyk, Magdalena, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019)

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study
por: Fanous, Helen, et al.
Publicado: (2013)

Population pharmacokinetics of immediate‐ and prolonged‐release tacrolimus formulations in liver, kidney and heart transplant recipients
por: Lu, Zheng, et al.
Publicado: (2019)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
por: Kamar, Nassim, et al.
Publicado: (2018)

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study
por: TruneČka, P., et al.
Publicado: (2015)

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence
por: Muduma, Gorden, et al.
Publicado: (2014)

A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
por: Herden, Uta, et al.
Publicado: (2021)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study
por: Friman, Styrbjörn, et al.
Publicado: (2021)

Long-term Prolonged-release Tacrolimus-based Immunosuppression in De Novo Kidney Transplant Recipients: 5-Y Prospective Follow-up of Patients in the ADVANCE Study
por: Pernin, Vincent, et al.
Publicado: (2023)

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)

Efficacy and safety of prolonged-release versus immediate-release tacrolimus in de novo liver transplant recipients in South Korea: a randomized open-label phase 4 study (MAPLE)
por: Kim, Myoung Soo, et al.
Publicado: (2019)

Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation
por: Chapman, William C., et al.
Publicado: (2017)

Tacrolimus Formulation, Exposure Variability, and Outcomes in Kidney Transplant Recipients
por: Lai, Elaine F., et al.
Publicado: (2022)

Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study
por: Fernandez Rivera, Constantino, et al.
Publicado: (2021)

The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations
por: Fontova, Pere, et al.
Publicado: (2023)

Short- and Long-term Outcomes of De Novo Liver Transplant Patients Treated With Once-Daily Prolonged-Release Tacrolimus
por: Okumura, Yuichiro, et al.
Publicado: (2017)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

The effect of Maintenance Treatment with Twice-daily or Prolonged Once-daily Tacrolimus Formulation on Visual Evoked Potentials in Stable Kidney Transplant Recipients
por: Kolonko, Aureliusz, et al.
Publicado: (2020)

Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study
por: Rubik, Jacek, et al.
Publicado: (2019)

A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study
por: Moal, Valérie, et al.
Publicado: (2019)

Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study
por: Lladó, Laura, et al.
Publicado: (2019)

Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients
por: Silva, Hélio Tedesco, et al.
Publicado: (2014)

Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial
por: Suwelack, Barbara, et al.
Publicado: (2020)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation
por: El‐Nahhas, Toqa, et al.
Publicado: (2021)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial
por: Mourad, Georges, et al.
Publicado: (2017)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice
por: Muduma, Gorden, et al.
Publicado: (2016)

Impact of Resolved Preformed, Persistent Preformed, and De Novo Anti-HLA Donor-Specific Antibodies in Kidney Transplant Recipients on Long-Term Renal Graft Outcomes
por: Gniewkiewicz, Michal, et al.
Publicado: (2023)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dm6m1s53ne3sd44inpqrv4v2pg